As of November 9, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Werewolf Therapeutics, Inc. The largest reported stake is Moll Peter's, at 5.2%. 16 filings are on record since August 14, 2025 (Schedule 13G, September 21, 2026).
Sell to companies like Werewolf Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Moll Peter · Sole voting: 2,537,138 · Shared voting: 0 · Sole dispositive: 2,537,138 · Shared dispositive: 0 · SCHEDULE 13G, 2026-09-21
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 1,985,541 · Sole dispositive: 0 · Shared dispositive: 1,985,541 · SCHEDULE 13D/A, 2026-07-02
- · Holder: RA Capital Management, L.P. · Percent: 6% · SCHEDULE 13D/A
- · Holder: RA Capital Management, L.P. · Percent: 7.5% · SCHEDULE 13D/A
- · Holder: RA Capital Management, L.P. · Percent: 10.6% · SCHEDULE 13D/A
Werewolf Therapeutics, Inc. has 16 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock 0,0001$ per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-02-13 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 5.2% | 2,537,138 | SCHEDULE 13G, 2026-09-21 | 2026-09-18 | |
| RA Capital Management, L.P. | 4.1% | 1,985,541 | SCHEDULE 13D/A, 2026-07-02 | 2026-06-30 |
| MPM BioVentures 2014, L.P. | 3.8% | 792,254 | SCHEDULE 13D/A, 2026-05-12 | 2026-05-08 |
| Longwood Fund III GP, LLC | 3.5% | 1,677,082 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 |
| PFM Health Sciences, LP | 0.9% | 401,110 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Werewolf Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Werewolf Therapeutics, Inc. and the records around it.
Werewolf Therapeutics, Inc. elsewhere on the record
- Layoff notices Feb 2026
- Who owns it
Companies that share a holder
- MPM BioVentures 2014, L.P. also filed stake reports on 1 other company: ENTRADA THERAPEUTICS, INC. (Sep 2026)
- PFM Health Sciences, LP also filed stake reports on 2 other companies: Outset Medical, Inc. (Feb 2026), PMV Pharmaceuticals, Inc. (Aug 2025)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch Werewolf Therapeutics, Inc.
Get an email when Werewolf Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Werewolf Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Werewolf Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Werewolf Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Moll Peter | 2,537,138 | 0 | 2,537,138 | 0 | SCHEDULE 13G, 2026-09-21 |
| RA Capital Management, L.P. | 0 | 1,985,541 | 0 | 1,985,541 | SCHEDULE 13D/A, 2026-07-02 |
| Peter Kolchinsky | 0 | 1,985,541 | 0 | 1,985,541 | SCHEDULE 13D/A, 2026-07-02 |
| Rajeev Shah | 0 | 1,985,541 | 0 | 1,985,541 | SCHEDULE 13D/A, 2026-07-02 |
| RA Capital Healthcare Fund, L.P. | 0 | 1,853,646 | 0 | 1,853,646 | SCHEDULE 13D/A, 2026-07-02 |
The latest filing identifies Werewolf Therapeutics, Inc. by CUSIP 95075A107 and gives its principal executive office as 303 WYMAN STREET, SUITE 300, WALTHAM, MA 02451 (SCHEDULE 13G, 2026-09-21).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | PFM Health Sciences, LP | 0.9% | SCHEDULE 13G/A |
| 2025-11-04 | MPM BioVentures 2014, L.P. | 13.4% | SCHEDULE 13D/A |
| 2025-11-06 | RA Capital Management, L.P. | 13.8% | SCHEDULE 13D/A |
| 2025-11-17 | MPM BioVentures 2014, L.P. | 11.3% | SCHEDULE 13D/A |
| 2025-12-03 | MPM BioVentures 2014, L.P. | 10% | SCHEDULE 13D/A |
| 2025-12-29 | MPM BioVentures 2014, L.P. | 8.2% | SCHEDULE 13D/A |
| 2026-01-16 | MPM BioVentures 2014, L.P. | 6.9% | SCHEDULE 13D/A |
| 2026-02-11 | Longwood Fund III GP, LLC | 3.5% | SCHEDULE 13G/A |
| 2026-05-05 | MPM BioVentures 2014, L.P. | 5.4% | SCHEDULE 13D/A |
| 2026-05-12 | MPM BioVentures 2014, L.P. | 3.8% | SCHEDULE 13D/A |
| 2026-05-14 | RA Capital Management, L.P. | 12.6% | SCHEDULE 13D/A |
| 2026-06-15 | RA Capital Management, L.P. | 10.6% | SCHEDULE 13D/A |
| 2026-06-22 | RA Capital Management, L.P. | 7.5% | SCHEDULE 13D/A |
| 2026-06-26 | RA Capital Management, L.P. | 6% | SCHEDULE 13D/A |
| 2026-07-02 | RA Capital Management, L.P. | 4.1% | SCHEDULE 13D/A |
| 2026-09-21 | Moll Peter | 5.2% | SCHEDULE 13G |
Questions about who owns Werewolf Therapeutics, Inc.
Who owns Werewolf Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Werewolf Therapeutics, Inc.: Moll Peter (5.2%, Schedule 13G, filed 2026-09-21).
When did Moll Peter buy into Werewolf Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Moll Peter on this page is the Schedule 13G, filed 2026-09-21, reporting 5.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Werewolf Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.